Dec 03, 2019
PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
Nov 26, 2019
Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora® for the Prevention of Pregnancy
Nov 13, 2019
Evofem Biosciences to Participate in Upcoming Investor Conferences
Sep 25, 2019
Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019
Aug 22, 2019
Evofem Biosciences to Present at Upcoming Healthcare Conferences
Jul 30, 2019
Evofem Biosciences to Report Second Quarter 2019 Results and Provide Corporate Update on August 6, 2019
May 14, 2019
Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference
May 07, 2019
Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
Jan 03, 2019
Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
Oct 09, 2018
Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress
Oct 03, 2018
Evofem Biosciences to Present Data on Methodology and Current Status of Two Ongoing Clinical Studies of Amphora at the 2018 International Federation of Gynecology and Obstetrics (FIGO) World Congress
Sep 21, 2018
New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress
Jul 27, 2017
Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) for Prevention of Pregnancy